<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01742988</url>
  </required_header>
  <id_info>
    <org_study_id>CUDC-907-101</org_study_id>
    <nct_id>NCT01742988</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma</brief_title>
  <official_title>Phase 1 Open Label, Multi-center, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered Fimepinostat (CUDC-907), a PI3K and HDAC Inhibitor, in Subjects With Refractory or Relapsed Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Curis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Leukemia and Lymphoma Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Curis, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, open-label, dose-escalation study of fimepinostat (CUDC-907) in patients
      with relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL), or high-grade B-cell
      lymphoma (HGBL) with or without MYC and BCL2 alterations. Fimepinostat (CUDC-907) is a
      multi-targeted agent designed to inhibit phosphoinositide 3-kinase (PI3K)and histone
      deacetylase (HDAC). The study is designed to assess the safety, the maximum tolerated dose,
      the recommended phase 2 dose (RP2D), pharmacokinetics and the anti-cancer activity of oral
      fimepinostat in combination with 1 or more anti-cancer regimens.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of oral fimepinostat (CUDC-907) in combination with venetoclax and rituximab</measure>
    <time_frame>At the end of cycle 1 or 2 (each cycle is 21 days)</time_frame>
    <description>To be evaluated in patients with relapsed and/or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Within any given study arm, the highest dose level studied at which fewer than 2 out of 6 subjects (&lt; 33%) experience a dose limiting toxicity (DLT).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the safety and tolerability of fimepinostat in combination with anti-cancer regimens by evaluating the number of participants with adverse events assessed using the NCI Common Terminology Criteria for Adverse Events (CTCAE, v4.0).</measure>
    <time_frame>18 months</time_frame>
    <description>Number of participants with adverse events assessed using the NCI Common Terminology Criteria for Adverse Events (CTCAE, v4.0).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the efficacy of fimepinostat in combination with anti-cancer regimens by evaluating ORR</measure>
    <time_frame>24 months</time_frame>
    <description>ORR assessments as measured using Lugano criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the efficacy of fimepinostat in combination with anti-cancer regimens by evaluating DOR</measure>
    <time_frame>24 months</time_frame>
    <description>DOR assessments as measured using Lugano criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess pharmacokinetics (PK) of fimepinostat when administered in combination with anti-cancer regimens as measured by area under the concentration-time curve (AUC).</measure>
    <time_frame>Pre-dose to 21 - 28 days post dose</time_frame>
    <description>Pharmacokinetic parameters will include area under the concentration-time curve (AUC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess pharmacokinetics (PK) of fimepinostat when administered in combination with anti-cancer regimens as measured by maximum plasma concentration (Cmax).</measure>
    <time_frame>Pre-dose to 21 - 28 days post dose</time_frame>
    <description>Pharmacokinetic parameters will include maximum plasma concentration (Cmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess pharmacokinetics (PK) of fimepinostat when administered in combination with anti-cancer regimens as measured by half-life (T1/2).</measure>
    <time_frame>Pre-dose to 21 - 28 days post dose</time_frame>
    <description>Pharmacokinetic parameters will include half-life (T1/2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess pharmacokinetics (PK) of fimepinostat when administered in combination with anti-cancer regimens as measured by clearance (Cl).</measure>
    <time_frame>Pre-dose to 21 - 28 days post dose</time_frame>
    <description>Pharmacokinetic parameters will include clearance (Cl).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess pharmacokinetics (PK) of fimepinostat when administered in combination with anti-cancer regimens as measured by volume of distribution (Vd).</measure>
    <time_frame>Pre-dose to 21 - 28 days post dose</time_frame>
    <description>Pharmacokinetic parameters will include volume of distribution (Vd).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess PK of venetoclax when administered in combination with fimepinostat as measured by area under the concentration-time curve (AUC).</measure>
    <time_frame>Pre-dose to 21 - 28 days post dose</time_frame>
    <description>Pharmacokinetic parameters will include area under the concentration-time curve (AUC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess PK of venetoclax when administered in combination with fimepinostat as measured by maximum plasma concentration (Cmax).</measure>
    <time_frame>Pre-dose to 21 - 28 days post dose</time_frame>
    <description>Pharmacokinetic parameters will include maximum plasma concentration (Cmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess PK of venetoclax when administered in combination with fimepinostat as measured by half-life (T1/2).</measure>
    <time_frame>Pre-dose to 21 - 28 days post dose</time_frame>
    <description>Pharmacokinetic parameters will include half-life (T1/2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess PK of venetoclax when administered in combination with fimepinostat as measured by clearance (Cl).</measure>
    <time_frame>Pre-dose to 21 - 28 days post dose</time_frame>
    <description>Pharmacokinetic parameters will include clearance (Cl).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess PK of venetoclax when administered in combination with fimepinostat as measured by volume of distribution (Vd).</measure>
    <time_frame>Pre-dose to 21 - 28 days post dose</time_frame>
    <description>Pharmacokinetic parameters will include volume of distribution (Vd).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of fimepinostat in combination with anti-cancer regimens as measured by OS.</measure>
    <time_frame>24 months</time_frame>
    <description>OS measured using RECIL 2017 criteria and revised RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of fimepinostat in combination with anti-cancer regimens as measured by PFS.</measure>
    <time_frame>24 months</time_frame>
    <description>PFS measured using RECIL 2017 criteria and revised RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of fimepinostat in combination with anti-cancer regimens as measured by ORR.</measure>
    <time_frame>24 months</time_frame>
    <description>ORR measured using RECIL 2017 criteria and revised RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of fimepinostat in combination with anti-cancer regimens as measured by DOR.</measure>
    <time_frame>24 months</time_frame>
    <description>DOR measured using RECIL 2017 criteria and revised RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate biomarkers of fimepinostat activity</measure>
    <time_frame>24 months</time_frame>
    <description>Exploratory biological markers of fimepinostat activity will be assessed in PBMCs, plasma, and tumor and samples to explore biomarkers that correlate with safety and/or efficacy, such as CREBBP/EP300.</description>
  </secondary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Lymphoma</condition>
  <condition>Relapsed Lymphoma</condition>
  <condition>Refractory Lymphoma</condition>
  <condition>Relapsed and/or Refractory Lymphoma</condition>
  <condition>Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL)</condition>
  <condition>Refractory Diffuse Large B-Cell Lymphoma (DLBCL)</condition>
  <condition>Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)</condition>
  <condition>Double-hit Lymphoma (DHL)</condition>
  <condition>Triple-hit Lymphoma (THL)</condition>
  <condition>Double-expressor Lymphoma (DEL)</condition>
  <condition>High-grade B-cell Lymphoma (HGBL)</condition>
  <arm_group>
    <arm_group_label>Fimepinostat - Continuous Once Daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fimepinostat 30-60 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fimepinostat - 2x/week</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fimepinostat 60-240 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fimepinostat - 3x/week</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fimepinostat 60-180 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fimepinostat - 4x/week</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fimepinosta 60-180 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fimepinostat - 5x/week</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fimepinostat 60-180 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fimepinostat - Expansion 5x/week</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fimepinostat 60 mg on the 5 days on/2 days off</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fimepinostat - Expansion 3x/week</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fimepinostat 120 mg 3 days on/4 days off</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fimepinostat 60 mg - Combination w/ rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fimepinostat 60 mg 5 days on.2 days off plus rituximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fimepinostat 120 mg - Combination w/ rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fimepinostat 120 mg 3x/week plus rituximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fimepinostat - Biocomparability Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biocomparability Arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fimepinostat 30 mg - Combination w/ venetoclax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fimepinostat 30 mg 5 days on/2 days off plus venetoclax. Different combinations of dose levels for venetoclax will be explored</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fimepinostat 60 mg - Combination w/ venetoclax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fimepinostat 60 mg 5 days on/2 days off plus venetoclax. Different combinations of dose levels for venetoclax will be explored</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fimepinostat - Combination w/ venetoclax and rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fimepinostat and venetoclax dosed at dose levels determined for that combination. Rituximab dosed at 375 mg/m2 IV on Day 1 of each 21 day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fimepinostat</intervention_name>
    <arm_group_label>Fimepinostat - 2x/week</arm_group_label>
    <arm_group_label>Fimepinostat - 3x/week</arm_group_label>
    <arm_group_label>Fimepinostat - 4x/week</arm_group_label>
    <arm_group_label>Fimepinostat - 5x/week</arm_group_label>
    <arm_group_label>Fimepinostat - Biocomparability Arm</arm_group_label>
    <arm_group_label>Fimepinostat - Combination w/ venetoclax and rituximab</arm_group_label>
    <arm_group_label>Fimepinostat - Continuous Once Daily</arm_group_label>
    <arm_group_label>Fimepinostat - Expansion 3x/week</arm_group_label>
    <arm_group_label>Fimepinostat - Expansion 5x/week</arm_group_label>
    <arm_group_label>Fimepinostat 120 mg - Combination w/ rituximab</arm_group_label>
    <arm_group_label>Fimepinostat 30 mg - Combination w/ venetoclax</arm_group_label>
    <arm_group_label>Fimepinostat 60 mg - Combination w/ rituximab</arm_group_label>
    <arm_group_label>Fimepinostat 60 mg - Combination w/ venetoclax</arm_group_label>
    <other_name>CUDC-907</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <arm_group_label>Fimepinostat - Combination w/ venetoclax and rituximab</arm_group_label>
    <arm_group_label>Fimepinostat 120 mg - Combination w/ rituximab</arm_group_label>
    <arm_group_label>Fimepinostat 60 mg - Combination w/ rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>venetoclax</intervention_name>
    <arm_group_label>Fimepinostat 30 mg - Combination w/ venetoclax</arm_group_label>
    <arm_group_label>Fimepinostat 60 mg - Combination w/ venetoclax</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥ 18 years of age with any of the following: Histopathologically confirmed
             DLBCL or HGBL (i.e., HGBL with MYC, BCL2, and/or BCL6 rearrangements, HGBL, not
             otherwise specified [NOS], or DLBCL, NOS) that is refractory to, or has relapsed
             after, treatment with at least 1 prior regimen. Eligible sub-types include DHL, THL,
             or DEL, as well as DLBCL or HGBL without MYC and/or BCL2 alterations. Criteria for DHL
             are concurrent MYC translocation+ and BCL2 translocation+ by fluorescence in situ
             hybridization (FISH) (same criteria for THL, which also includes BCL6 translocation+
             by FISH); criteria for DEL are concurrent overexpression of MYC (≥ 40%) and BCL2 (&gt;
             50%) by immunohistochemistry (IHC).

          -  Measurable disease by CT or PET/CT. MRI acceptable as per protocol.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

          -  Recovery to Grade 1 or baseline of any toxicity due to prior systemic treatments
             (excluding alopecia).

          -  Absolute neutrophil count ≥ 1,000/µL; platelets ≥ 75,000/µL for patients with no bone
             marrow involvement by malignancy; platelets ≥ 50,000/µL for patients with bone marrow
             involvement by malignancy.

          -  Creatinine ≤ 1.5x upper limit of normal (ULN); total bilirubin ≤ 1.5x ULN; AST/ALT ≤
             2.5x ULN.

          -  Life expectancy of at least 3 months.

        Exclusion Criteria:

          -  Intention to undergo stem cell transplant (SCT) or treatment with chimeric antigen
             receptor (CAR) T-cell therapy.

          -  SCT therapy within 100 days prior to starting study treatment.

          -  Systemic anti-cancer therapy or investigational agent within 3 weeks of study entry,
             except for nitrosoureas or mitomycin C (6 weeks).

          -  Other non-cytotoxic anti-cancer therapy or investigational agent within 5 half-lives
             or 21 days prior to study treatment, whichever is shorter, as long as any drug related
             toxicities have resolved to Grade 1 or less. Dexamethasone up to 12 mg/d is allowed as
             supportive therapy and does not exclude participation.

          -  Contraindication to venetoclax or rituximab.

          -  Progressive disease during treatment or within 3 months of stopping prior treatment
             with a BCL2 inhibitor, histone deacetylase (HDAC) inhibitor, or phosphoinositide-3
             kinase (PI3k) inhibitor, or prior discontinuation of any of these therapies due to
             clinically significant toxicity.

          -  Graft vs. host disease following prior allogeneic transplant within 3 months prior to
             study treatment.

          -  Ongoing treatment with chronic immunosuppressants.

          -  Active CNS lymphoma.

          -  Known gastrointestinal condition that would interfere with swallowing or the oral
             absorption or tolerance of fimepinostat.

          -  Serious infection requiring systemic antibiotic therapy within 14 days prior to study
             treatment.

          -  Uncontrolled or severe cardiovascular disease

          -  Unstable or clinically significant concurrent medical condition.

          -  Second primary malignancy within 2 years of study entry other than what is specified
             in the protocol.

          -  Known HIV positive, hepatitis B surface antigen-positive status, or known or suspected
             active hepatitis C infection.

          -  Active CMV infection, presence of CMV antigenemia, or evidence of any invasive CMV end
             organ disease (e.g., CMV colitis).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute, Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center, University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 4, 2012</study_first_submitted>
  <study_first_submitted_qc>December 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2012</study_first_posted>
  <last_update_submitted>March 20, 2020</last_update_submitted>
  <last_update_submitted_qc>March 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>DLBCL</keyword>
  <keyword>MYC</keyword>
  <keyword>Diffuse Large B-Cell Lymphoma</keyword>
  <keyword>HGBL</keyword>
  <keyword>High-grade B-Cell Lymphoma</keyword>
  <keyword>Double-hit Lymphoma (DHL)</keyword>
  <keyword>Triple-hit Lymphoma (THL)</keyword>
  <keyword>Double-expressor Lymphoma (DEL)</keyword>
  <keyword>P13K</keyword>
  <keyword>HDAC</keyword>
  <keyword>Open-Label</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

